Napoleone Ferrara
Italian-American molecular biologist / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Napoleone Ferrara?
Summarize this article for a 10 year old
Napoleone Ferrara (born 26 July 1956 in Catania) is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy.[1] At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers.[citation needed] Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.[citation needed]
Napoleone Ferrara | |
---|---|
Born | (1956-07-26) 26 July 1956 (age 67) |
Alma mater | |
Known for | VEGF discovery |
Awards | |
Scientific career | |
Institutions | |